Neogen Corp. (NEOG) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1158021,
    "name": "Neogen Corp.",
    "stock_name": "Neogen Corp.",
    "full_name": "Neogen Corp.",
    "name_url": "stocks-analysis/neogen-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.93",
    "chg": 0.01,
    "chgp": "0.17%",
    "dir": 1,
    "prev_price": "5.92",
    "mcapval": "1,229.38",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US6404911066",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "5.93 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/neogen-corp-1158021-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Neogen Corp. Stock Hits Day Low of $5.57 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/neogen-corp-stock-hits-day-low-of-557-amid-price-pressure-3601739",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NeogenCorp_priceRelatedfactors_3601739.png",
        "date": "2025-10-07 22:22:05",
        "description": "Neogen Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has faced significant challenges, with a notable decline in stock price and returns over the past year. Key financial indicators reveal low return on capital employed and a high debt-equity ratio, highlighting ongoing struggles in the market."
      },
      {
        "title": "Is Neogen Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-neogen-corp-technically-bullish-or-bearish-3545262",
        "imagepath": "",
        "date": "2025-09-20 19:07:33",
        "description": "As of 12 August 2025, the technical trend for Neogen Corp. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly chart but are bearish on the monthly. Moving averages are mildly bearish on the daily timeframe. The KST is mildly bullish weekly but bearish monthly, while the Dow Theory indicates a mildly bearish weekly and mildly bullish monthly trend. The OBV shows a mildly bearish weekly and mildly bullish monthly trend as well.\n\nIn terms of performance, Neogen Corp. has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -53.29% compared to the S&P 500's 12.22%, and a one-year return of -67.11% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a weak outlook despite some bul..."
      },
      {
        "title": "Is Neogen Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-neogen-corp-overvalued-or-undervalued-3541978",
        "imagepath": "",
        "date": "2025-09-20 17:41:14",
        "description": "As of 30 July 2024, the valuation grade for Neogen Corp. has moved from expensive to risky, indicating a significant shift in its perceived value. Based on the current metrics, Neogen Corp. appears to be overvalued. The P/E ratio stands at an exceptionally high 281, while the Price to Book Value is only 0.42, suggesting that the market price is not justified by the company's book value. Additionally, the EV to EBITDA ratio is 10.94, which further highlights the disparity between the company's valuation and its earnings potential.\n\nIn comparison to its peers, Neogen Corp. has a P/E ratio that is significantly higher than Masimo Corp. at 179.74 and Globus Medical, Inc. at 18.37, both of which are in a better valuation position. Furthermore, the company's return performance has been notably poor, with a YTD return of -53.29% compared to the S&P 500's 12.22%, and a staggering 10Y return of -84.97% against the S..."
      }
    ],
    "total": 8,
    "sid": "1158021",
    "stock_news_url": "https://www.marketsmojo.com/news/neogen-corp-1158021"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Neogen Corp. Stock Hits Day Low of $5.57 Amid Price Pressure

2025-10-07 22:22:05

Neogen Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has faced significant challenges, with a notable decline in stock price and returns over the past year. Key financial indicators reveal low return on capital employed and a high debt-equity ratio, highlighting ongoing struggles in the market.

Is Neogen Corp. technically bullish or bearish?

2025-09-20 19:07:33

As of 12 August 2025, the technical trend for Neogen Corp. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly chart but are bearish on the monthly. Moving averages are mildly bearish on the daily timeframe. The KST is mildly bullish weekly but bearish monthly, while the Dow Theory indicates a mildly bearish weekly and mildly bullish monthly trend. The OBV shows a mildly bearish weekly and mildly bullish monthly trend as well. In terms of performance, Neogen Corp. has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -53.29% compared to the S&P 500's 12.22%, and a one-year return of -67.11% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a weak outlook despite some bul...

Is Neogen Corp. overvalued or undervalued?

2025-09-20 17:41:14

As of 30 July 2024, the valuation grade for Neogen Corp. has moved from expensive to risky, indicating a significant shift in its perceived value. Based on the current metrics, Neogen Corp. appears to be overvalued. The P/E ratio stands at an exceptionally high 281, while the Price to Book Value is only 0.42, suggesting that the market price is not justified by the company's book value. Additionally, the EV to EBITDA ratio is 10.94, which further highlights the disparity between the company's valuation and its earnings potential. In comparison to its peers, Neogen Corp. has a P/E ratio that is significantly higher than Masimo Corp. at 179.74 and Globus Medical, Inc. at 18.37, both of which are in a better valuation position. Furthermore, the company's return performance has been notably poor, with a YTD return of -53.29% compared to the S&P 500's 12.22%, and a staggering 10Y return of -84.97% against the S...

View All News